* Africa-Israel Ltd., Chaired by Lev Levayev, currently has $250 million invested in projects in the Czech capital, Prague. The latest Africa-Israel project is an entertainment and business complex in the city, valued at in the city, valued at $65 million. Levayev says that the company intends to increase its investments in Europe by $300 million, to be invested in real estate, energy and communications.
* Israeli software company Incognito will fill a $6 million order from France Telecom. The company will supply of software for filtering Internet content.
* Celltifk will supply the Swedish telecommunications company Ericsson with a system it has developed for global cellular network operators. The Israeli firm specializes in development of interactive broadcasting technology for cellular networks.
* Dedicado, the main supplier of broad-band communications services in Uruguay, has contracted the Israeli company Elviran, to provide a system for rapid wireless access. The order is worth more than $2 million.
* Israel's Teva Pharmaceutical Industries announced that the US Food and Drug Administration has issued final approval for the company's ANDA for Enalapril Maleate/Hydrochlorothiazide tablets, the generic equivalent of Merck's anti-hypertensive drug Vaseretic, and for Flutamide Capsules, the generic equivalent of Schering Corp's anti-neoplastic drug, Eulexin Capsules. The brand name products had 2000 sales of approximately $57 million and $48 million, respectively. Teva plans to launch immediately, in both cases.
* Israeli software company Incognito will fill a $6 million order from France Telecom. The company will supply of software for filtering Internet content.
* Celltifk will supply the Swedish telecommunications company Ericsson with a system it has developed for global cellular network operators. The Israeli firm specializes in development of interactive broadcasting technology for cellular networks.
* Dedicado, the main supplier of broad-band communications services in Uruguay, has contracted the Israeli company Elviran, to provide a system for rapid wireless access. The order is worth more than $2 million.
* Israel's Teva Pharmaceutical Industries announced that the US Food and Drug Administration has issued final approval for the company's ANDA for Enalapril Maleate/Hydrochlorothiazide tablets, the generic equivalent of Merck's anti-hypertensive drug Vaseretic, and for Flutamide Capsules, the generic equivalent of Schering Corp's anti-neoplastic drug, Eulexin Capsules. The brand name products had 2000 sales of approximately $57 million and $48 million, respectively. Teva plans to launch immediately, in both cases.